Arginase 1 is a key driver of immune suppression in pancreatic cancer
eLife · 2023
DOI: 10.7554/elife.80721 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2023. Verfasst von Rosa E Menjivar und 19 weiteren Autor:innen. Beteiligte Einrichtung: Cellular and Molecular Biology Program, University of Michigan-Ann Arbor, Ann Arbor, United States. Hauptthemen laut MEDLINE: Arginase, Pancreatic Neoplasms. Die Arbeit wurde bisher 176-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, NIH HHS.
Abstract (Originalsprache)
An extensive fibroinflammatory stroma rich in macrophages is a hallmark of pancreatic cancer. In this disease, it is well appreciated that macrophages are immunosuppressive and contribute to the poor response to immunotherapy; however, the mechanisms of immune suppression are complex and not fully understood. Immunosuppressive macrophages are classically defined by the expression of the enzyme Arginase 1 (ARG1), which we demonstrated is potently expressed in pancreatic tumor-associated macrophages from both human patients and mouse models. While routinely used as a polarization marker, ARG1 also catabolizes arginine, an amino acid required for T cell activation and proliferation. To investigate this metabolic function, we used a genetic and a pharmacologic approach to target Arg1 in pancreatic cancer. Genetic inactivation of Arg1 in macrophages, using a dual recombinase genetically engineered mouse model of pancreatic cancer, delayed formation of invasive disease, while increasing CD8 + T cell infiltration. Additionally, Arg1 deletion induced compensatory mechanisms, including Arg1 overexpression in epithelial cells, namely Tuft cells, and Arg2 overexpression in a subset of macrophages. To overcome these compensatory mechanisms, we used a pharmacological approach to inhibit arginase. Treatment of established tumors with the arginase inhibitor CB-1158 exhibited further increased CD8 + T cell infiltration, beyond that seen with the macrophage-specific knockout, and sensitized the tumors to anti-PD1 immune checkpoint blockade. Our data demonstrate that Arg1 drives immune suppression in pancreatic cancer by depleting arginine and inhibiting T cell activation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cellular and Molecular Biology Program, University of Michigan-Ann Arbor, Ann Arbor, United States.
- Department of Molecular and Integrative Physiology, University of Michigan-Ann Arbor, Ann Arbor, United States.
- Department of Surgery, University of Michigan-Ann Arbor, Ann Arbor, United States.
- Cancer Biology Program, University of Michigan-Ann Arbor, Ann Arbor, United States.
- Department of Immunology, University of Michigan-Ann Arbor, Ann Arbor, United States.
- Department of Cell and Developmental Biology, University of Michigan-Ann Arbor, Ann Arbor, United States.
ORCID-Profile: Rosa E Menjivar, Allison Bischoff, Daniel Salas-Escabillas, Eileen Carpenter, Costas A Lyssiotis, Marina Pasca di Magliano
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- NIH HHS
- NICHD NIH HHS
- NIDDK NIH HHS
- NIAID NIH HHS
- National Institutes of Health
- National Cancer Institute
Zitieren
APA
Menjivar, R. E., Nwosu, Z. C., Du, W., Donahue, K. L., Hong, H. S., Espinoza, C., Brown, K., Velez-Delgado, A., Yan, W., Lima, F., Bischoff, A., Kadiyala, P., Salas-Escabillas, D., Crawford, H. C., Bednar, F., Carpenter, E., Zhang, Y., Halbrook, C. J., Lyssiotis, C. A., & Pasca di Magliano, M. (2023). Arginase 1 is a key driver of immune suppression in pancreatic cancer. eLife. https://doi.org/10.7554/elife.80721
Vancouver
Menjivar RE, Nwosu ZC, Du W, Donahue KL, Hong HS, Espinoza C, et al. Arginase 1 is a key driver of immune suppression in pancreatic cancer. eLife. 2023. doi:10.7554/elife.80721
BibTeX
@article{Menjivar2023,
author = {Menjivar, Rosa E and Nwosu, Zeribe C and Du, Wenting and Donahue, Katelyn L and Hong, Hanna S and Espinoza, Carlos and Brown, Kristee and Velez-Delgado, Ashley and Yan, Wei and Lima, Fatima and Bischoff, Allison and Kadiyala, Padma and Salas-Escabillas, Daniel and Crawford, Howard C and Bednar, Filip and Carpenter, Eileen and Zhang, Yaqing and Halbrook, Christopher J and Lyssiotis, Costas A and Pasca di Magliano, Marina},
title = {Arginase 1 is a key driver of immune suppression in pancreatic cancer},
journal = {eLife},
year = {2023},
doi = {10.7554/elife.80721}
}
EUVIMED